Table 1 Patient data from five patients with COVID-19 who received dornase alfa with albuterol March–April, 2020
Patient | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
Clinical Characteristics | |||||
Date of admission | 29 March | 4 April | 16 March | 16 March | 26 March |
Age | 56 | 34 | 65 | 31 | 34 |
Gender | F | M | M | M | F |
Ethnicity | Hispanic | White | Asian | Hispanic | Black |
BMI | 38 | 41 | 32 | 30 | 38 |
Date of ICU admission | 31 March | 4 April | 16 March | 18 March | 26 March |
Comorbidities | |||||
Hypertension | Yes | Yes | Yes | Yes | |
Diabetes mellitus, type 2 | Yes | ||||
Asthma | Yes | Yes | Yes | ||
Hyperlipidemia | Yes | ||||
Migraine | Yes | ||||
Chronic gastritis | Yes | ||||
ECMO | |||||
Date of ECMO initiation | – | 4 April | – | 27 March | 28 March |
Date of ECMO cessation | – | 16 April | – | 10 April | 20 April |
Dornase alfa (DA) + albuterol (A) parameters | |||||
Administration (DA: 2.5 mg, A: 2.5 mg, both twice daily using the Aerogen® Solo nebulizer) | |||||
Date of DA + A initiation | 9 April | 4 April | 31 March | 1 April | 31 March |
Date of DA + A cessation | 14 April | 6 April | 8 April | 19 April | 24 April |
Toxicities | None | None | None | None | None |
Other COVID-19 treatment | |||||
Methylprednisolone | Yes | Yes | Yes | Yes | |
Anakinra | Yes | Yes | |||
CytoSorb | Yes | ||||
Anticoagulants a | |||||
Enoxaparin | 40 mg BID | 120 mg BID | 40 mg BID | 100 mg BID | 120 mg BID |
Argatroban | Yes | Yes | Yes | ||
Heparin gtt | Yes | Yes | |||
Venous thromboembolism | None | None | None | Right SDVT Right CVT | None |
Current State | ICU discharge | ICU discharge | ICU discharge | ICU discharge | ICU discharge |